La Paz Signs Research Agreement with J&J on 'Microneedle-Particle' Technology

[Asia Economy Reporter Hyungsoo Park] Lapas, a developer of microneedle pharmaceutical patches, announced on the 9th that it has signed a research agreement with Asia Pacific Johnson & Johnson Innovation for the use of microneedle-particle patent technology.

Although Lapas cannot disclose specific details due to a confidentiality agreement, it explained that it will develop a new type of product utilizing microneedle-particle technology through close collaboration with Dr.Ci:Labo. Dr.Ci:Labo is Johnson & Johnson's skincare specialty brand.

The microneedle-particle technology, patented by Lapas in September last year, can extensively deliver active ingredients stored in microneedles to the skin. It has the advantage of having no restrictions on the application area by using skincare product ingredients.

Since Lapas's microneedle particles can be used together with cream-type cosmetics, the company expects that based on the synergy generated when used in combination, it will become a new representative product form in the cosmetics market.

Park Hyunwoo, Director of Lapas Cosmetics Business Division, said, "Lapas's microneedle-particle technology can effectively deliver active ingredients to the skin," adding, "We will take the lead in commercializing the technology, expanding its application to the general cosmetics field, and focusing on launching new hit products."

This content was produced with the assistance of AI translation services.